Lataa...
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
BACKGROUND: Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have shown impressive therapeutic results. However, only 20–40% of advanced melanoma patients have durable responses to ICI, and these positive effects must be balanced against severe off-target immune toxicity and...
Tallennettuna:
| Julkaisussa: | Front Oncol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5625582/ https://ncbi.nlm.nih.gov/pubmed/29034210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2017.00233 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|